Comment on: MRI characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort: Reply
Rheumatology (Oxford)
.
2024 Apr 2;63(4):e142-e143.
doi: 10.1093/rheumatology/kead413.
Authors
Xenofon Baraliakos
1
,
Effie Pournara
2
,
Laura C Coates
3
,
Victoria Navarro-Compán
4
,
Ricardo Blanco
5
,
Eamonn O'Brien
6
,
Barbara Schulz
2
,
Robert Landewe
7
Affiliations
1
Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany.
2
Global Medical Affairs, Immunology, Novartis Pharma AG, Basel, Switzerland.
3
Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
4
Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain.
5
Divisions of Immunology, Endocrinology, and Rheumatology, Hospital University Marqués de Valdecilla, Santander, Spain.
6
Novartis Ireland Ltd., Dublin, Ireland.
7
Department of Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
PMID:
37616495
DOI:
10.1093/rheumatology/kead413
No abstract available
MeSH terms
Arthritis, Psoriatic* / diagnostic imaging
Humans
Magnetic Resonance Imaging
Sacroiliac Joint
Grants and funding
Novartis Pharma